Arizona Tribune - Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

NYSE - LSE
CMSC 0.63% 19.08 $
BCE 0.18% 22.06 $
RBGPF -0.46% 75.3 $
GSK -1.36% 48.58 $
BP -3.7% 43.25 $
AZN -1.96% 178.76 $
RIO -4.7% 75.9 $
RYCEF 1.5% 17.36 $
BTI -1.13% 58.5 $
NGG -0.41% 82.22 $
BCC 0.87% 65.71 $
CMSD 0.75% 18.78 $
VOD -2.49% 14.85 $
RELX -0.95% 39.02 $
JRI -1.11% 10.85 $
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, wants to remind you of our September 10th webcast at 8:30 am Eastern Time, which can be accessed here or to call in, please dial 888-506-0062 (toll free in the US), +1 973-528-0011 (if International) and use the participant access code 289672. We look forward to reviewing the data with you tomorrow morning.

Text size:

A copy of the original press release announcing data can be found here.
A copy of the presentation to be reviewed can be found here.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and the treatment of chronic kidney disease.

For more information on Revelation, please visit https://www.revbiosciences.com.

Company Contact

Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: [email protected]

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: [email protected]

SOURCE: Revelation Biosciences, Inc.



View the original press release on ACCESS Newswire

G.P.Martin--AT